Comparison of Viral Infection Rates after T-cell Depletion in Pediatric HCT: Alemtuzumab Vs Post-Transplant Cyclophosphamide (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #862; 647; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "The alemtuzumab group was younger (median 7.7 vs 13.9 years) and, as expected, primarily received MUD transplants (85%), while the PTCy group mainly received haploidentical transplants (63%); letermovir use was similar between groups (Table 1). In this pediatric HCT cohort, viral infection rates were comparable between alemtuzumab and PTCy. Despite the small sample size, both T-cell depletion approaches appear to pose comparable infectious risks, supporting tailored platform choice based on donor and clinical factors. 1."
Clinical • Post-transplantation • Infectious Disease • Pediatrics • Transplantation
|
|
Alexis Kuhn, PharmD, BCOP 1,2; Catherine Martin, PharmD, BCOP 1,2; Mira Kohorst, MD 2; Asmaa Ferdjallah, MD, MPH 2; Paul Galardy, MD 2; Anand Srinivasan, M.B.B.S 2
|